Quantcast
Last updated on April 19, 2014 at 9:20 EDT

Latest Lorus Therapeutics Inc. Stories

2013-12-02 08:30:31

Avanish Vellanki and Gregory K. Chow Join as Chief Business Officer and Chief Financial Officer TORONTO, Dec. 2, 2013 /PRNewswire/ -- Lorus Therapeutics Inc. (TSX: LOR) ("Lorus" or the "Company") today announced the appointment of Avanish Vellanki as Chief Business Officer (CBO) and Gregory K. Chow as Chief Financial Officer (CFO) of the Company. In his role as CBO, Mr. Vellanki will manage global business development, licensing and corporate strategy. Mr. Chow will have global...

2008-10-09 09:00:52

Lorus Therapeutics Inc. (Lorus) (TSX: LOR)(AMEX: LRP), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today reported financial results for the three months ended August 31, 2008. Unless specified otherwise, all amounts are in Canadian dollars. JUNE 1, 2008 TO DATE HIGHLIGHTS: - Completed a rights offering to eligible shareholders raising net proceeds of $3.2 million. - Successfully...

2008-07-29 09:00:24

TORONTO, ONTARIO--(Marketwire - July 29, 2008) - Lorus Therapeutics Inc. (TSX:LOR)(AMEX:LRP) ("Lorus"), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today announced the allowance of a new patent from the United States Patent and Trademark Office for its clinical-stage anticancer drug LOR-2040. The patent, which was issued this month as U.S. Patent No. 7,405,205, protects methods of treating...

2008-07-21 08:45:08

TORONTO, July 21 /PRNewswire-FirstCall/ -- Lorus Therapeutics Inc. (Lorus), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today reported financial results for the three and twelve months ended May 31, 2008. Unless specified otherwise, all amounts are in Canadian dollars. 2008 HIGHLIGHTS - Initiation of GLP toxicology studies for Lorus' lead anticancer small molecule drug...

2008-07-09 09:00:13

TORONTO, July 9 /PRNewswire-FirstCall/ -- Lorus Therapeutics Inc. (TSX: LOR, AMEX: LRP) ("Lorus" or the "Corporation"), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today announced progress made in the Virulizin(R) development program, including the publication of two research studies on the Virulizin(R) mode of action and the issuance of a new patent for Virulizin(R) in Mexico....

2008-07-02 09:01:03

TORONTO, July 2 /PRNewswire-FirstCall/ -- Lorus Therapeutics Inc. (TSX: LOR, AMEX: LRP) ("Lorus" or the "Corporation"), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today announced publication by an Ohio State University (OSU) clinical team of a paper entitled "Phase I Study of GTI-2040, an Antisense to Ribonucleotide Reductase, in Combination with High-Dose Cytarabine in Patients with Acute...

2006-02-01 07:53:44

TORONTO (Reuters) - Lorus Therapeutics Inc. said on Wednesday data from Phase 3 trials of its Virulizin(R) cancer treatment showed a significant survival benefit for a subgroup of patients. The Canadian company said the finding from its exploratory analysis would not be sufficient for regulatory approval without additional clinical investigation. Lorus said patients who remained on Virulizin(R) demonstrated a median survival of 10.9 months, compared with 7.4 months for patients on a...